Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) is scheduled to be releasing its earnings data before the market opens on Wednesday, August 9th.

Foamix Pharmaceuticals Ltd. (NASDAQ FOMX) opened at 4.73 on Monday. The stock’s 50 day moving average is $5.05 and its 200 day moving average is $6.54. The company’s market cap is $176.06 million. Foamix Pharmaceuticals Ltd. has a 52-week low of $4.03 and a 52-week high of $11.27.

TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/foamix-pharmaceuticals-ltd-nasdaqfomx-scheduled-to-post-earnings-on-wednesday.html.

A number of research analysts have issued reports on the company. Zacks Investment Research cut Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 9th. Credit Suisse Group reissued a “buy” rating and set a $9.00 price objective on shares of Foamix Pharmaceuticals in a report on Wednesday, July 19th.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.